Amedisys Inc (NASDAQ:AMED) – Equities researchers at Oppenheimer issued their Q1 2019 EPS estimates for Amedisys in a note issued to investors on Tuesday. Oppenheimer analyst M. Wiederhorn expects that the health services provider will post earnings of $0.63 per share for the quarter. Oppenheimer also issued estimates for Amedisys’ Q2 2019 earnings at $0.71 EPS, Q3 2019 earnings at $0.71 EPS, Q4 2019 earnings at $0.74 EPS and FY2019 earnings at $2.79 EPS.

Amedisys (NASDAQ:AMED) last released its quarterly earnings results on Tuesday, November 7th. The health services provider reported $0.56 EPS for the quarter, topping the consensus estimate of $0.54 by $0.02. The business had revenue of $380.20 million during the quarter, compared to analyst estimates of $384.59 million. Amedisys had a net margin of 2.88% and a return on equity of 14.68%. The company’s quarterly revenue was up 5.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.36 earnings per share.

AMED has been the subject of several other research reports. Mizuho raised shares of Amedisys from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $55.00 to $65.00 in a report on Thursday, November 2nd. Benchmark raised shares of Amedisys from a “hold” rating to a “buy” rating and set a $56.00 price objective for the company in a report on Thursday, November 2nd. Craig Hallum reaffirmed a “buy” rating and issued a $68.00 price objective (up previously from $55.00) on shares of Amedisys in a report on Thursday, November 9th. Jefferies Group reaffirmed a “buy” rating and issued a $60.00 price objective on shares of Amedisys in a report on Thursday, October 12th. Finally, SunTrust Banks reaffirmed a “buy” rating and issued a $60.00 price objective on shares of Amedisys in a report on Monday, October 9th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and seven have assigned a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $61.00.

Amedisys (AMED) traded down $1.29 during trading on Wednesday, hitting $55.74. 408,825 shares of the stock traded hands, compared to its average volume of 380,800. The company has a market capitalization of $1,858.37, a price-to-earnings ratio of 44.59, a P/E/G ratio of 1.17 and a beta of 0.71. Amedisys has a fifty-two week low of $43.48 and a fifty-two week high of $65.91. The company has a quick ratio of 1.33, a current ratio of 1.33 and a debt-to-equity ratio of 0.16.

A number of hedge funds and other institutional investors have recently modified their holdings of AMED. Point72 Asset Management L.P. lifted its holdings in Amedisys by 337.0% in the 3rd quarter. Point72 Asset Management L.P. now owns 474,044 shares of the health services provider’s stock valued at $26,528,000 after acquiring an additional 674,044 shares during the last quarter. American Century Companies Inc. lifted its holdings in Amedisys by 41.4% in the 3rd quarter. American Century Companies Inc. now owns 1,671,680 shares of the health services provider’s stock valued at $93,547,000 after acquiring an additional 489,220 shares during the last quarter. Wells Fargo & Company MN lifted its holdings in Amedisys by 29.7% in the 3rd quarter. Wells Fargo & Company MN now owns 1,484,041 shares of the health services provider’s stock valued at $83,048,000 after acquiring an additional 339,825 shares during the last quarter. Balyasny Asset Management LLC acquired a new stake in Amedisys in the 2nd quarter valued at about $7,736,000. Finally, Bank of New York Mellon Corp lifted its holdings in Amedisys by 10.8% in the 3rd quarter. Bank of New York Mellon Corp now owns 846,575 shares of the health services provider’s stock valued at $47,375,000 after acquiring an additional 82,247 shares during the last quarter. 94.50% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This news story was reported by Daily Political and is the sole property of of Daily Political. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of international trademark and copyright laws. The legal version of this news story can be read at https://www.dailypolitical.com/2018/01/17/q1-2019-earnings-forecast-for-amedisys-inc-amed-issued-by-oppenheimer.html.

About Amedisys

Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.

Earnings History and Estimates for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.